|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:methotrexate
gptkb:embryonal_carcinoma
gptkb:Alimta
|
|
gptkbp:activities
|
DNA cross-linking
|
|
gptkbp:appointed_by
|
hospital settings
intravenous injection
|
|
gptkbp:approves
|
gptkb:1978
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Platinol
|
|
gptkbp:can_be_used_with
|
gptkb:paclitaxel
gptkb:etoposide
gptkb:gemcitabine
|
|
gptkbp:class
|
platinum-based drug
|
|
gptkbp:clinical_trial
|
ongoing
palliative care
adjuvant therapy
neoadjuvant therapy
|
|
gptkbp:combatants
|
high for DNA
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to cisplatin
|
|
gptkbp:developed_by
|
gptkb:United_States
|
|
gptkbp:discovered_by
|
gptkb:1965
gptkb:Barnett_Rosenberg
|
|
gptkbp:dissolved
|
water-soluble
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:financial_performance
|
light sensitive
|
|
gptkbp:frequency
|
every 3-4 weeks
|
|
gptkbp:historical_significance
|
first platinum-based chemotherapy drug
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
cisplatin
|
|
gptkbp:impact
|
improves survival rates
|
|
gptkbp:indication
|
solid tumors
|
|
gptkbp:ingredients
|
C6 H6 Cl2 N4
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_monitored_by
|
renal function
hearing tests
blood counts
|
|
gptkbp:is_used_for
|
treating cancer
|
|
gptkbp:lifespan
|
30-60 hours
|
|
gptkbp:metabolism
|
not extensively metabolized
|
|
gptkbp:previous_name
|
gptkb:cisplatin
|
|
gptkbp:research_areas
|
oncology
|
|
gptkbp:research_focus
|
improving efficacy
reducing toxicity
combating resistance
|
|
gptkbp:side_effect
|
nausea
vomiting
hearing loss
kidney damage
|
|
gptkbp:social_structure
|
square planar
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:synergizes_with
|
radiation therapy
|
|
gptkbp:targets
|
gptkb:healthcare_organization
ovarian cancer
bladder cancer
|
|
gptkbp:weight
|
300.1 g/mol
|